PDCD1 and head and neck squamous cell carcinoma: Anti-PD-1/PD-L1-naïve HNSCC patients who received the combined therapy (n = 34) had a significantly higher overall response rate and disease control rate compared to patients received GSK3359609 alone (n = 17) (226).